Cyclacel Pharmaceuticals, Inc. CYCC · Stock Open Cyclacel Pharmaceuticals, Inc. in new tab
Cyclacel Pharmaceuticals, Inc. Analysis (CYCC)
Is Cyclacel Pharmaceuticals, Inc. a good investment? Cyclacel Pharmaceuticals, Inc. (CYCC) is currently trading at 6.37 USD.
In terms of valuation, the stock trades at a P/E ratio of 0.00. This relatively low multiple may signal that Cyclacel Pharmaceuticals, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Cyclacel Pharmaceuticals, Inc. is expected to release its next earnings report on Nov. 10, 2025. The market consensus estimate for Forward EPS is -1.99.
Investor FAQ
Does Cyclacel Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Cyclacel Pharmaceuticals, Inc.?
Cyclacel Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 10, 2025. The company currently has a trailing EPS of 7123.50.
Company Profile
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
| Year | Total Dividends |
|---|---|
| ▸2025 |
0.00 USD
|
| May 1, 2025 | 0.0006 |
| ▸2016 |
0.00 USD
|
| Aug. 1, 2016 | 0.0005 |
| Split Date | Split Ratio to 1 |
|---|---|
| May 12, 2025 | 0.060000 |
| July 7, 2025 | 0.070000 |
Community Discussion